Sonoma Pharmaceuticals Revenues Jump 60% as it Hits First Positive Adjusted EBITDA

Key Facts

In a move reflecting a successful expansion strategy within the healthcare sector, Sonoma Pharmaceuticals reported strong financial results for its first fiscal quarter. According to reports, total revenue increased by 60% year-over-year to $6.4 million, driven by rising demand for its Microcyn technology-based products. The company also achieved its first-ever positive adjusted EBITDA, while net loss per share decreased by 88%.

This robust financial performance was primarily driven by massive growth in the U.S. market, where revenues surged by 141%, helping expand the gross margin to 40%. These results are attributed to stable operating expenses, new FDA clearances, and the signing of new global distribution agreements that have strengthened the company's market position.

Looking ahead, investors are monitoring the sustainability of this operational profitability and how international expansions will impact future results. As current price data for SNOA is unavailable at the August 6, 2026 close, focus remains on operational execution. Global markets are also awaiting key economic catalysts, including the interest rate decision in Japan and the Eurozone CPI release in late July, which may influence risk appetite for small-cap stocks.